Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ

被引:2
作者
Humbeck, Lina [1 ,2 ]
Pretzel, Jette [1 ]
Spitzer, Saskia [1 ]
Koch, Oliver [1 ,3 ]
机构
[1] TU Dortmund Univ, Fac Chem & Chem Biol, D-44227 Dortmund, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Computat Chem, Med Chem, Birkendorferstr 65, D-88397 Biberach, Germany
[3] Westfalische Wilhelms Univ Munster, Inst Pharmaceut & Med Chem, D-48149 Munster, Germany
关键词
DRUG DISCOVERY; PROTEIN; INHIBITORS; DESIGN; POTENT; VISUALIZATION; PHARMACOLOGY; EXPLORATION; UNIVERSE; TARGET;
D O I
10.1021/acschembio.1c00323
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Knowledge about interrelationships between different proteins is crucial in fundamental research for the elucidation of protein networks and pathways. Furthermore, it is especially critical in chemical biology to identify further key regulators of a disease and to take advantage of polypharmacology effects. Here, we present a new concept that combines a scaffold-based analysis of bioactivity data with a subsequent screening to identify novel inhibitors for a protein target of interest. The initial scaffold-based analysis revealed a flavone-like scaffold that can be found in ligands of different unrelated proteins indicating a similarity in ligand binding. This similarity was further investigated by testing compounds on bromodomain-containing protein 4 (BRD4) that were similar to known ligands of the other identified protein targets. Several new BRD4 inhibitors were identified and proven to be validated hits based on orthogonal assays and X-ray crystallography. The most important discovery was an unexpected relationship between BRD4 and peroxisome-proliferator activated receptor gamma (PPAR gamma). Both proteins share binding site similarities near a common hydrophobic subpocket which should allow the design of a polypharmacology-based ligand targeting both proteins. Such dual-BRD4-PPAR gamma modulators open up new therapeutic opportunities, because both are important drug targets for cancer therapy and many more important diseases. Thereon, a complex structure of sulfasalazine was obtained that involves two bromodomains and could be a potential starting point for the design of a bivalent BRD4 inhibitor.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 50 条
  • [41] Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites
    Olp, Michael D.
    Sprague, Daniel J.
    Goetz, Christopher J.
    Kathman, Stefan G.
    Wynia-Smith, Sarah L.
    Shishodia, Shifali
    Summers, Steven B.
    Xu, Ziyang
    Statsyuk, Alexander V.
    Smith, Brian C.
    ACS CHEMICAL BIOLOGY, 2020, 15 (04) : 1036 - 1049
  • [42] Brd4 modulates diet-induced obesity via PPAR.-dependent Gdf3 expression in adipose tissue macrophages
    Hu, Xiangming
    Dong, Xingchen
    Li, Guo
    Chen, Yanheng
    Chen, Jinjing
    He, Xiaoxin
    Sun, Hao
    Kim, Dong-Hyun
    Kemper, Jongsook Kim
    Chen, Lin-Feng
    JCI INSIGHT, 2021, 6 (07)
  • [43] BRD4 (Bromodomain-Containing Protein 4) Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes
    Padmanabhan, Arun
    Alexanian, Michael
    Linares-Saldana, Ricardo
    Gonzalez-Teran, Barbara
    Andreoletti, Gaia
    Huang, Yu
    Connolly, Andrew J.
    Kim, Wonho
    Hsu, Austin
    Duan, Qiming
    Winchester, Sarah A. B.
    Felix, Franco
    Perez-Bermejo, Juan A.
    Wang, Qiaohong
    Li, Li
    Shah, Parisha P.
    Haldar, Saptarsi M.
    Jain, Rajan
    Srivastava, Deepak
    CIRCULATION, 2020, 142 (24) : 2338 - 2355
  • [44] Pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation, and biological evaluation for the discovery of novel BRD4 inhibitors
    Yan, Guoyi
    Hou, Manzhou
    Luo, Jiang
    Pu, Chunlan
    Hou, Xueyan
    Lan, Suke
    Li, Rui
    CHEMICAL BIOLOGY & DRUG DESIGN, 2018, 91 (02) : 478 - 490
  • [45] Cell-Based Protein Stabilization Assays for the Detection of Interactions between Small-Molecule Inhibitors and BRD4
    Schulze, Jessica
    Moosmayer, Dieter
    Weiske, Joerg
    Fernandez-Montalvan, Amaury
    Herbst, Christopher
    Jung, Marie
    Haendler, Bernard
    Bader, Benjamin
    JOURNAL OF BIOMOLECULAR SCREENING, 2015, 20 (02) : 180 - 189
  • [46] Discovery of a Novel Selective PPARγ Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow
    Kouskoumvekaki, Irene
    Petersen, Rasmus K.
    Fratev, Filip
    Taboureau, Olivier
    Nielsen, Thomas E.
    Oprea, Tudor I.
    Sonne, Si B.
    Flindt, Esben N.
    Jonsdottir, Svava Osk
    Kristiansen, Karsten
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2013, 53 (04) : 923 - 937
  • [47] A Ligand's View of Target Similarity: Chemogenomic Binding Site-Directed Techniques for Drug Discovery
    Garland, Stephen L.
    Gloriam, David E.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (15) : 1872 - 1881
  • [48] Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer
    Zhang, Yonglei
    Zheng, Long
    Ma, Liangliang
    Yin, Fucheng
    Luo, Zhongwen
    Li, Shang
    Jiang, Yuhan
    Kong, Lingyi
    Wang, Xiaobing
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (23) : 21186 - 21207
  • [49] Discovery of Novel Inhibitors of BRD4 for Treating Prostate Cancer: A Comprehensive Case Study for Considering Water Networks in Virtual Screening and Drug Design
    Zhong, Haiyang
    Wang, Xinyue
    Chen, Shicheng
    Wang, Zhe
    Wang, Huating
    Xu, Lei
    Hou, Tingjun
    Yao, Xiaojun
    Li, Dan
    Pan, Peichen
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 67 (01) : 138 - 151
  • [50] Unexpected similarity between HIV-1 reverse transcriptase and tumor necrosis factor binding sites revealed by computer vision
    Eguida, Merveille
    Rognan, Didier
    JOURNAL OF CHEMINFORMATICS, 2021, 13 (01)